Avost Eye Drops

Avost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.

Avost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.


Avost Eye Drops is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of or insufficiently responsive to another intraocular pressure lowering medication, as monotherapy or as adjunctive therapy.

Avost is also used to associated treatment for these conditions: Increased Intra Ocular Pressure (IOP)

Trade Name Avost
Generic Travoprost
Other Names Travoprost, Travoprostum
Weight 04%
Type Eye Drops
Formula C26H35F3O6
Weight Average: 500.5477
Monoisotopic: 500.238573467
Protein binding

The binding of travoprost free acid to plasma proteins is moderate at 80% and linear over a 10,000-fold concentration range (0.10 - 100 ng/mL) .

Therapeutic Class Drugs for miotics and glaucoma
Manufacturer Ibn-Sina Pharmaceuticals Ltd
Available Country Bangladesh
Last Updated: June 23, 2021 at 11:26 am


Avost dosage

Use in adults: The recommended dose is one drops of Avost in the conjunctival sac of the affected eye (s) once daily in the evening, If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. When substituting another ophthalmic antiglaucoma agent with Avost, discontinue the other agent and start the following day with Avost.

Pediatric patients: The efficacy and safety of travoprost eye drops in patients below the age of 18 years have not been established.

Side Effects

The most frequently reported treatment-related side-effect is ocular hyperaemia.


Avost should be used with caution in patients with active intraocular inflammation (iritis/uveitis). Avost should not be administered while wearing contact lenses. Contact lenses should be removed prior to the administration of the solution. Lenses may be reinserted 15 minutes following administration of Avost.


Reduced therapeutic effect with NSAIDs.

Food Interaction

No interactions found.

Volume of Distribution

Given the data currently available, it has been recorded that travoprost free acid is moderately distributed into body tissues with a volume of distribution of 2.6 L/kg in rats .

Half Life

The terminal elimination half-life of travoprost free acid is determined to be approximately 45 minutes, although studies demonstrated half-life values that ranged from 17 to 86 minutes .


Data regarding the clearance of travoprost is not readily available or accessible.

Pregnancy & Breastfeeding use

There are no adequate and well-controlled clinical study En pregnant women. Avost should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether the drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when travoprost is administered to a lactating woman.


Avost eye drops is contraindicated in patients with hypersensitive to travoprost or any excipients of Avost.

Storage Condition

Store in a cool, dry place and protected from light. Keep out of reach of children. Discard the container 4 weeks after opening.

Avost contains Travoprost see full prescribing information from innovator Monograph